Phaseolus – Green bean pod (Phaseoli fructus (sine semine))
|Latin name of the genus:||Phaseolus|
|Latin name of herbal substance:||Phaseoli fructus (sine semine)|
|Botanical name of plant:||Phaseolus vulgaris l.|
|English common name of herbal substance:||Green bean pod|
Latin name of the genus: Phaseolus
Latin name of herbal substance: Phaseoli fructus (sine semine)
Botanical name of plant: Phaseolus vulgaris L.
English common name of herbal substance: Green bean pod
1.1. Description of the herbal substance(s), herbal preparation(s) or combinations thereof
Phaseolus vulgaris L. belongs to the family of Fabaceae.
The herbal substance consists of the dried pericarpium freed of the seeds of Phaseolus vulgaris L. According to the DAC 1986, the water soluble extractive is not less than 12%; the seed fragments are not more than 4%, and foreign matter not more than 2%. Ash is not more than 8% (DAC 1986).
In English, it is referred to as green bean, kidney bean, French bean, common bean or haricot bean.
It is referred to as Fructus phaseoli sine semine or Phaseoli pericarpium in Latin, Bohnenhülsen and Schminckbohne in German and ‘Gousses d’haricot’ in French.
Phaseolus is known as an ancient cultivated plant. The herbal substance comes from cultivated plants grown in various European countries (amongst others Bulgaria, Hungary, the former USSR and former Yugoslavia) (Wichtl 1984; Wichtl 1994; Czech Pharmaceutical Codex 1993).
The herbal substance is described in other compendia and textbooks.
Kidney bean pods consist of the fruit wall, freed from the seeds. The material is in the form of yellowish white, somewhat curled, thin pieces of the up to 15 cm long fruit wall. The outside surface is pale yellow and slightly wrinkled; the inside is covered with a whitish, shiny membrane (endocarp and inner mesocarp layers). Occasionally, yellow fragments of the stalks are present.
The herbal substance is without smell and with slightly mucilaginous taste. Authentication of the plant is done macro- and microscopically. The exocarp has a strong wrinkled cuticle, roundish stomata, and cicatrices. In the outer layers, the mesocarp consists of short,
The Czech Pharmaceutical Codex (1993) describes identification tests:
a)Legume freed from seeds. Often slightly
b)Microscopy. Epidermis of the exocarp consists of polygonal, equilateral cells with scars after trichomes and circular stomata without adjacent cells, with firmly wrinkled cuticle. The mesocarp consists of several layers of
According to the Czech Pharmaceutical Codex (1993), the following characteristics should be respected:
a)Foreign matters (ČSL 4, page 100/I)
b)Different coloured drug maximum 5%
c)Foreign organic matter maximum 1%
d)Inorganic matter maximum 0.5%
e)Loss on drying maximum 10% (ČSL 4, page 100/I)
f)Ash maximum 7% (ČSL 4, page 100/I)
g)Asch insoluble in hydrochloric acid maximum 2% (ČSL 4, page 100/I)
The herbal substance contains arginine and silicic acid, as well as chromium salts (cf. antidiabetic activity).
The composition of the pods is different from that of the beans. The kidney beans themselves (Phaseolus vulgaris fructus) contain several phytochemicals, whereof the most important compounds are described as follows:
The carbohydrates which can be divided in starch and
A specific derivate of isoflavonoids, found in Phaseolus vulgaris, is phaseolin, an
The lectins, including phytohaemagglutinin (PHA), show a haemagglutinin activity. These compounds are heat sensitive, which makes it possible to reduce the lectin activity by extrusion or home cooking. Trypsin inhibitors are also influenced by extrusion and home cooking, because these methods reduce the protease inhibiting activity
It should be noted that the beans themselves are not considered in the monograph and that their use is different from that of the pods. Only preparations that are exposed to heat during manufacturing are recommended for human use. Since lectins and trypsin inhibitors are heat sensitive, their activity is reduced and, with that, the toxicity of Phaseolus vulgaris (see also section 3.3). The extracts contain a high amount of
The comminuted herbal substance is used as a herbal tea for oral use.
•Combinations of herbal substance(s) and/or herbal preparation(s) including a description of vitamin(s) and/or mineral(s) as ingredients of traditional combination herbal medicinal products assessed, where applicable.
1.2. Information about products on the market in the Member States
Regulatory status overview
Other TRAD: Other national Traditional systems of registration Other: If known, it should be specified or otherwise add ’Not Known’
This regulatory overview is not legally binding and does not necessarily reflect the legal status of the products in the MSs concerned.
1.3. Search and assessment methodology
Publications from PubMed were used after limiting the search by including only articles where Phaseolus vulgaris was mentioned in title and/or abstract. The promising references of the found publications were also investigated either in PubMed, local journals or specific websites. Other sources were a number of handbooks available to the Rapporteur (see list of references).
Specific search terms* resulted in 26 interesting articles to analyze.
15 articles included
Similar search terms in ‘Embase’ ** (427 hits) and ‘Web Of Science’ resulted in 7 new articles in ‘Embase’.
38 articles included
* Specific search terms in PubMed:
11 articles excluded
The references of the included articles were screened for relevant titles. The corresponding abstracts were analyzed and interesting articles were observed.
–“Phaseolus/adverse effects”[Mesh] OR “Phaseolus/poisoning”[Mesh] OR “Phaseolus/toxicity”[Mesh]
–(phaseolus[Title/Abstract] AND vulgaris[Title/Abstract]) AND (Clinical Trial[ptyp] OR Randomised Controlled Trial[ptyp] OR Review[ptyp])
–(phaseolus[Title/Abstract] AND vulgaris[Title/Abstract]) AND in vitro[ptyp]
–phaseolus[Title/Abstract] AND vulgaris[Title/Abstract] AND weight[Title/Abstract] AND loss[Title/Abstract]
–phaseolus[Title/Abstract] AND vulgaris[Title/Abstract] AND diabetes[Title/Abstract] ** Specific search terms in Embase:
–“Phaseolus vulgaris extract”
–‘Phaseolus’/syn AND vulgaris AND [human]/lim AND [english]lim AND [abstracts]/lim
Further narrowing of the number of articles used in support of the AR took place during the establishment of the monograph.
2. Historical data on medicinal use
2.1. Information on period of medicinal use in the Community
Historical research (Helmstädter 2010)
Bean pods were already described by Dodoens (1608) as having a diuretic activity and compared to Asparagus for this action. Phaseolus vulgaris preparations were described in medical records in 1908. M. Kaufmann (Germany) wrote a review of oral drugs with supposed antidiabetic activity. He mentioned three case studies where bean pod tea was tested, but appeared to be ineffective. A published article in 1923 by J. Bertram Collip (Canada) described the application of an alcoholic extract of ‘bean greens’ (leaves and stems) to rabbits. After 12 hours, a reduction by 20% of blood sugar levels was obtained after an initial rise. In 1927, Prof. E. Kaufmann (Germany) published a series of articles where aqueous and ethanolic extracts of bean pods were part of the experiments. There was a moderate hypoglycaemic effect in normal rabbits. Furthermore, patients of a clinical study showed decreases of blood sugar values within 4 hours. Geβner and Siebert (Germany) investigated in 1928 the effect of aqueous and alcoholic extracts of bean pods in rabbits. The results showed decreases in blood glucose values. Also in 1928, Eisler and Portheim (Austria) performed in vitro studies with alcoholic extracts of bean pods. The next investigators were Gohr and Hilgenberg (Germany) in 1929. They used the same commercial extract as that studied by Geβner and Siebert, but administered it to dogs. Only in hyperglycaemic dogs, significant decreases were obtained. The same extract was used by Gebhardt (Germany) in 1930, who investigated the effect in starving rabbits and diabetic patients. Since not all rabbits/patients showed reductions of the blood sugar values, he considered the extract as not effective. In 1932, Hartleb (Poland) obtained contradictory results after administration of an extract in healthy and diabetic patients. He concluded that the extract’s effect was unpredictable, but may have some use in the treatment of diabetes. Lapp (Austria) claimed in 1937 that bean pod tea reduced the blood glucose levels of healthy people, but not in diabetic patients.
2.2. Information on traditional/current indications and specified substances/preparations
Table 1: Overview of traditional uses of bean pods
Since 2001 investigations were more concentrated on the beans themselves (Phaseoli vulgaris semen). However, commenting upon the results obtained with the beans is out of scope of this assessment report, as the use of bean extracts does not belong to the tradition of 30 years reported in the present document.
2.3. Specified strength/posology/route of administration/duration of use for relevant preparations and indications
Phaseolus (bean pods) is present in 2 herbal combination teas, which are only sold in that pharmacy where they are manufactured, therefore only a very restricted and only local importance can be given to Phaseolus containing products.
There are no products containing Phaseolus vulgaris with marketing authorisation or registration in Bulgaria. There is no information available for food supplements.
There is a herbal tea on the market since 1969 containing Phaseoli fructus sine semine as well as Myrtilli herba, Salviae officinalis herba, Galegae herba, Polygoni avicularis herba, Taraxaci radix cum herba, Rubi fruticosi folium, Foeniculi fructus and Bardanae radix.
Indication: traditionally used as an adjuvant in diabetes.
Phaseoli fructus sine semine has been described in the Český farmaceutický kodex (Czech Pharmaceutical Codex) since 1993, with the following recommended dosage: for oral use, single dose = 3 g in a form of a decoction; pharmacological group: phytopharmaceutical (diuretic, antidiabetic).
There are no medicinal products containing Phaseolus vulgaris in Estonia. Other products containing this plant are probably classified as food supplements, under notification at the Veterinary and Food Board.
In Germany, there is one authorised combination product (tablets). It contains Phaseoli fructus sine semine and Urticae herba, Rosae pseudofructus cum fructibus, Equiseti herba, Betulae folium. Indication: Traditionally used to support the elimination function of the kidney.
There are no
The NAMMD authorised in 2001 Phaseoli fructus sine seminibus as raw material (there was such a requirement before accession to the EU) which, further on, was included in a combination product, authorised in 2003 as adjuvant in diabetes mellitus. No products with Phaseoli fructus sine seminibus as single component have been authorised by NAMMD.
Table 2: Information about therapeutic regimen supporting traditional use
Table 3: Other information about therapeutic regimen
3.1. Overview of available pharmacological data regarding the herbal substance(s), herbal preparation(s) and relevant constituents thereof
Research on hypoglycaemic effect (overview by Helmstädter 2010)
In contrast to the two previous studies, no effect of an aqueous extract (prepared from 15 g of powdered pods in 300 ml of water), given in a dose of 25 g of extract/kg, was seen on streptozotocin diabetic mice in an oral glucose tolerance test by Neef et al. in 1995.
An article published in 2003 by Pari and Venkateswaran mentions the glucose lowering effects of a hot aqueous extract prepared from Phaseolus vulgaris pods (200 mg/kg) on streptozotocin diabetic rats. The administration of the extract resulted in a significant hypoglycaemic effect. Both the extract and glibenclamide reversed the decrease of the hexokinase and
Table 4: Studies on hypoglycaemic effect
Table extracted from
Figure extracted from
Table extracted from Pari et al. 2004: The fasting blood glucose and plasma insulin values.
Several in vivo studies were performed to investigate the influence of the Phaseolus vulgaris preparations on the blood glucose values.
One study used decocted green bean pods: 132 g of dried plant were boiled in 1 l water on slow heat for 10 minutes, cooled at room temperature and filtered
The bean pod preparations reduced the hyperglycaemia and had a lowering effect on fasting blood glucose in hyperglycaemic rats. The doses used in the studies amounted to high levels (up to 500 mg extract per kg body weight), which makes extrapolation to human conditions difficult. However doses dependency can be considered as a positive fact.
Reporting on the investigations with beans (Phaseoli fructus) and preparations thereof is out of scope of this assessment report. References on the investigations with bean extracts are included separately in the list of references (see References not supporting the assessment report).
3.2. Overview of available pharmacokinetic data regarding the herbal substance(s), herbal preparation(s) and relevant constituents thereof
No data available.
3.3. Overview of available toxicological data regarding the herbal substance(s)/herbal preparation(s) and constituents thereof
Toxicological data found in literature are on the beans (Phaseoli fructus) and cannot be extrapolated to bean pods (Phaseoli fructus sine semine).
3.4. Overall conclusions on
In vivo studies were performed with beans as well as with bean pod preparations. Rats (normal as well as hyperglycaemic and obese) and rabbits were used as animal species. Only outcomes related to bean
pods are presented in this assessment report. Bean pod preparations reduced the glycaemia and increased insulin activity. No
4. Clinical Data
4.1. Clinical Pharmacology
4.1.1. Overview of pharmacodynamic data regarding the herbal substance(s)/preparation(s) including data on relevant constituents
A clinical trial with 18 healthy volunteers, aged 29 (±4.8) with a BMI of 23 (± 3.7) performed by Cerović et al. in 2006, showed no significant effects on glucose tolerance. The participants received either dry Phaseolus vulgaris extract from bean pods or placebo 30 minutes before a 50 g oral glucose tolerance test. Blood samples were drawn at 0, 15, 30, 60, 90 and 120 minutes.
4.1.2. Overview of pharmacokinetic data regarding the herbal substance(s)/preparation(s) including data on relevant constituents
No data available.
4.2. Clinical Efficacy
4.2.1. Dose response studies
No dose response studies available.
4.2.2. Clinical studies (case studies and clinical trials)
The only clinical studies available are investigations done with extracts of the beans (Phaseoli fructus) on weight reduction and hypoglycaemic effect as endpoints. However these data are out of scope for this assessment report.
4.2.3. Clinical studies in special populations (e.g. elderly and children)
No data available.
4.3. Overall conclusions on clinical pharmacology and efficacy
All clinical studies were performed with bean preparations instead of the traditionally used bean pods. As a consequence a possible therapeutic role for bean pods (Phaseoli fructus sine semine) is not supported by clinical evidence. The efficacy or pharmacological effects of the bean pods in the indication found in the monograph are plausible on the basis of
5. Clinical Safety/Pharmacovigilance
5.1. Overview of toxicological/safety data from clinical trials in humans
No data available.
5.2. Patient exposure
No data available. As there are no constituents of concern in bean pods and there exists a longstanding use of the substance as a food, the use of the preparations thereof may be considered as safe.
5.3. Adverse events and serious adverse events and deaths
By lack of clinical studies, no clinical safety data were systematically collected. There are no other clinical toxicological data available. If contamination of bean pods with beans should occur, there might be a theoretical risk of adverse events caused by the beans. Therefore some adverse effects caused by beans are presented below.
One case of severe anaphylaxis to Phaseolus vulgaris has been reported. Ingestion of cooked kidney beans caused a systemic reaction by a
Inhalation of vapours from cooked white bean induced two episodes of angioedema in a
5.4. Laboratory findings
5.5. Safety in special populations and situations
Interaction with oral hypoglycaemic drugs and insulin is possible due to the blood sugar level reducing effect. No studies on the effect of preparations from green bean pods during pregnancy and lactation have been performed. No investigations on handling machinery or driving vehicles were conducted.
5.6. Overall conclusions on clinical safety
No clinical data are available on toxicity of bean pods (Phaseoli fructus sine semine). Theoretically the concomitant use with antidiabetic drugs can result in an interaction. Patients using oral hypoglycaemic drugs and insulin may require further attention. Nevertheless, bean pods can be considered as safe because of the composition and the long history of use as a food substance.
6. Overall conclusions
No adverse reactions were reported with bean pods.
No Community list entry can be established.
No clinical studies were done with the bean pods. Based upon historical reporting, a traditional use of bean pods (Phaseoli fructus sine semine) can be granted. This tradition points to the use as a mild diuretic.
The bean pods (Phaseoli fructus sine semine) can be considered as a traditional herbal medicinal product used to increase the amount of urine to achieve flushing of the urinary tract as an adjuvant in minor urinary tract complaints. The recommended posology is 2.5 g comminuted herbal substance in 150 ml of boiling water as a herbal infusion, to be taken 2 to 6 times per day.
Therapeutic area: ‘Urinary tract and gynaecology disorders’.